Punjab-Based Company Booked For Producing ‘Substandard’ Antibiotic

Noida: The drugs control department of Gautam Budh Nagar on Tuesday booked a Mohali-based pharmaceutical company for allegedly producing “substandard” quality antibiotics, which were found being sold in Gautam Budh Nagar.

The medicine ‘AZitas (azithromycin)’ which is commonly used to treat infections, was being sold at the medical stores operating in Gautam Budh Nagar, and was found to be of ‘substandard’ quality during assessment, informed officials.

Inspections are ongoing under the directions of the food safety and drug administration department and Gautam Budh Nagar district magistrate Manish Kumar Verma, to ensure drugs being sold at medical stores and pharmacies in the district were meeting the safety standards.

A case has been registered against the errant manufacturer under Drugs and Cosmetics Act, 1940, and further legal action is underway, said Vaibhav Babbar, drug inspector, Gautam Budh Nagar.

“The assessment of the AZitas tablet revealed that the drug was of substandard quality and unfit for consumption. Manufacturing and selling of drugs which are unsuitable for consumption is prohibited and is a violation under Section 18 (prohibition of manufacture and sale of certain drugs and cosmetics),” Babbar, adding that the offence is punishable under Section 27 of the Drugs and Cosmetics Act, 1940.

The drugs control department of Gautam Budh Nagar last week registered a case against two manufacturers/producers based in Himachal Pradesh for allegedly manufacturing and selling ‘unfit’ antibiotic medicines.

Inspections at medical stores and pharmacies revealed the two medicines, “moxfaith” and ”moxaveri”, were ‘substandard’ or ‘adulterated’ and unsafe for consumption.

The drugs were confiscated and the two manufacturing companies were booked under relevant sections of the Drugs and Cosmetics Act, 1940.

Related Posts

  • Pharma
  • July 10, 2025
  • 98 views
Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

India stands tall as a pharmaceutical powerhouse, supplying 20% of the world’s generic medicines and nearly 62% of global vaccines. Yet, this success now faces a storm: US President Donald…

  • Pharma
  • July 10, 2025
  • 93 views
Novartis wins approval for first malaria drug for newborns and babies

ZURICH: Novartis (NOVN.S), opens new tab said on Tuesday it had received approval in Switzerland for Coartem Baby, which it said was the first drug to treat malaria in babies…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

Novartis wins approval for first malaria drug for newborns and babies

Novartis wins approval for first malaria drug for newborns and babies

Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr

Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr